MI-EATON
Power management company Eaton will display its Vehicle Group's innovative portfolio of internal combustion solutions for commercial vehicles Sept. 20-25 at the IAA Transportation show in Hannover, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220906005013/en/
Eaton’s Vehicle Group offers a portfolio of technologies that reduce emissions and improve fuel economy in commercial vehicles today and well into the future. (Photo: Business Wire)
"Although the transition to electrification is progressing, OEMs continue to seek improvements in fuel emissions and consumption for internal combustion engines," said Traci Melville, senior vice president and general manager, Global Products, Eaton's Vehicle Group. "In fact, according to KGP Powertrain Intelligence, there will be more than 30 million commercial vehicles produced with a diesel engine over the next decade."
Variable Valve Actuation technologies are flexible, reduce emissions
Eaton's Variable Valve Actuation (VVA) solutions are flexible and adaptable to any valvetrain architecture, allowing OEM customers to implement one or multiple functions that can significantly reduce carbon dioxide (CO2) and nitrogen oxides (NOx) emissions and lower fuel use.
Cylinder deactivation keeps selective catalytic reduction (SCR) at optimal temperatures by operating just two or three cylinders rather than all six in light-load conditions. That effectively delivers higher exhaust temperatures from the functioning cylinders at low speeds and loads or when the truck is neutral coasting, two conditions that can quickly cool aftertreatment systems. Concurrently, cylinder deactivation also lowers fuel consumption.
Late intake valve closing improves the engine's thermal efficiency, enabling a higher compression ratio, which reduces CO2 emissions and increases exhaust gas temperature that contributes to aftertreatment performance.
TVS EGR pump more controllable than competitive offerings
Eaton's positive-displacement TVS® exhaust gas recirculation (EGR) pump enables the use of a high-efficiency turbo to reduce engine pumping losses and increase fuel economy. The TVS® EGR pump is driven by a 48-volt electric motor, making it completely independent from engine speed and significantly more controllable than pumpless EGR systems.
Decompression engine brake compact, integrates into small engines
Eaton's decompression engine brake technology enhances brake power in the full engine operating range and is compact for easy integration into smaller engines.
Eaton's engine decompression brake is a valvetrain system with a mechanism to quickly switch between driving and engine braking mode according to customer requirements and can be integrated into a standard assembly.
Eaton's valves operate in demanding engine applications
Eaton offers a portfolio of differing valves, including monometallic and bimetallic, solid and hollow sodium cooled, seat faced and coated, providing a suitable solution for all vehicle applications. Eaton is developing new valve technologies for future commercial vehicles, including those with hydrogen internal combustion engines (ICE). Unlike traditional diesel-powered commercial vehicle engines, hydrogen ICE powertrains can operate dry combustion at extremely elevated temperatures depending on engine calibration.
Eaton is leveraging its nearly 100 years of experience in valve production to support hydrogen applications and the next generation of diesel engines. One possible solution is a sodium-filled hollow valve, which enables internal cooling. Wear protection is ensured by selecting the proper materials and coatings among the several grades available in Eaton's portfolio.
Eaton, Tenneco offer exhaust thermal management system to reduce emissions
Eaton and Tenneco launched a joint development agreement between Eaton's Vehicle Group and Tenneco's Clean Air business to produce an integrated exhaust thermal management system that enables commercial truck manufacturers to meet upcoming emissions regulations.
The integrated exhaust thermal management system provides heat directly to the vehicle's aftertreatment system, which is essential for reducing harmful exhaust emissions. Eaton's electrically driven TVS® blower precisely controls the airflow so the system can maintain optimal aftertreatment temperatures.
48-volt electric catalyst heater controller provides precise aftertreatment control
Eaton offers an air-cooled electric catalyst heater controller as part of its broader 48-volt electrical system portfolio. It contains several technologies that allow manufacturers to integrate 48-volt architectures into next-generation commercial vehicles. The controller manages the power delivered to the aftertreatment heater and is designed to receive commands from the aftertreatment system and provide soft-start and soft-stop capabilities for maintaining system voltage control.
48-volt DC-DC Converter for dual-voltage electrical systems
Eaton is developing a DC-DC Converter for 48V system architectures that will enable future powertrains to comply with new emissions regulations and provide higher levels of electrical power for CO2 reduction and autonomous driving systems. Unlike competitive offerings, Eaton's DC-DC converters are operational in ambient temperatures up to 85 degrees Celsius and boast 97% design efficiency.
Supercapacitors for 48-volt system power storage
Eaton has a current portfolio of supercapacitors for use in commercial vehicle applications, including 48V commercial vehicle systems. In addition, Eaton is developing advanced technology to further increase the level of power and energy storage capacity in these products.
Supercapacitors can quickly charge and discharge at higher rates than lithium-ion batteries. While the size and weight are comparable to lithium-ion packs, supercapacitors don't retain high levels of energy in comparison, do not require a liquid cooling system and have a longer cycle life.
Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. Eaton is guided by its commitment to do business right, to operate sustainably and to help its customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, Eaton is accelerating the planet's transition to renewable energy, helping to solve the world's most urgent power management challenges, and doing what's best for its stakeholders and all of society.
Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005013/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom